• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[血小板输注:临床方面、随访及并发症]

[Thrombocyte transfusion: clinical aspects, follow-up and complications].

作者信息

Söhngen D, Schneider W

机构信息

Medizinische Klinik und Poliklinik, Heinrich-Heine-Universität, Düsseldorf.

出版信息

Klin Wochenschr. 1991 Jun 18;69(9):379-86. doi: 10.1007/BF01647409.

DOI:10.1007/BF01647409
PMID:1921239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7095859/
Abstract

Thrombocytopenia is the most common cause of bleeding tendency, and, if due to impaired platelet production, is best treated by platelet transfusions. Prophylactic transfusions for asymptomatic patients should be considered if platelet count is below 20,000/microliters. However, if bleeding occurs or surgery is inevitable, platelet count should be maintained above 50,000/microliters. The benefit of platelet transfusions has to be balanced against risks like fever, infections and haemolysis. The effectiveness of platelet transfusions should be examined after 1 and 24 hrs by measuring the corrected count increment (CCI). Not only alloimmunization is a reason for unsatisfactory platelet increments. A poor CCI can also be due to fever, sepsis, hepato-splenomegaly or special drugs, which must be taken into account when assessing the demand for platelet transfusions.

摘要

血小板减少是出血倾向最常见的原因,若因血小板生成受损所致,最佳治疗方法是输注血小板。若血小板计数低于20,000/微升,对于无症状患者应考虑预防性输血。然而,若发生出血或手术不可避免,血小板计数应维持在50,000/微升以上。输注血小板的益处必须与发热、感染和溶血等风险相权衡。输注血小板1小时和24小时后,应通过测量校正计数增加值(CCI)来检查其有效性。血小板增加值未达预期不仅是同种免疫所致。CCI不佳也可能是由于发热、脓毒症、肝脾肿大或特殊药物引起,在评估血小板输注需求时必须考虑这些因素。

相似文献

1
[Thrombocyte transfusion: clinical aspects, follow-up and complications].[血小板输注:临床方面、随访及并发症]
Klin Wochenschr. 1991 Jun 18;69(9):379-86. doi: 10.1007/BF01647409.
2
[Ex-vivo bleeding time as a control for platelet transfusion].
Beitr Infusionsther Transfusionsmed. 1994;32:459-66.
3
[Thrombocyte substitution, 2: Thrombocyte preparations and determining the effectiveness of thrombocyte transfusion].
Z Gesamte Inn Med. 1986 Dec 1;41(23):647-51.
4
Predictive value of lymphocytotoxic test and platelet aggregometry for the effect of transfused platelet concentrates.
Haematologia (Budap). 1981 Dec;14(4):375-81.
5
[Thrombocyte transfusion: increase in platelets in relation to clinical and immunologic prerequisites].[血小板输注:与临床和免疫学前提条件相关的血小板增加情况]
Infusionsther Klin Ernahr. 1987 Apr;14 Suppl 2:10-4.
6
Post-transfusion platelet responses in critically ill cancer patients with hypoproliferative thrombocytopenia.危重症癌症伴低增生性血小板减少症患者的输血后血小板反应。
Transfusion. 2020 Feb;60(2):275-284. doi: 10.1111/trf.15596. Epub 2019 Nov 14.
7
Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.输注重组人血小板生成素来源的自体冻存血小板以支持化疗相关严重血小板减少症的安全性和有效性:一项随机交叉研究。
Lancet. 2002 Jun 22;359(9324):2145-52. doi: 10.1016/S0140-6736(02)09090-6.
8
[Thrombocyte transfusion].
Schweiz Rundsch Med Prax. 1987 Dec 8;76(50):1395-7.
9
Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets. Comparison between platelet concentrates derived from pooled buffy coates and apheresis.使用体外出血时间和输注血小板校正计数增加值评估血小板功能。比较来自混合白膜层和单采血小板的浓缩血小板。
Vox Sang. 1996;70(2):69-75. doi: 10.1111/j.1423-0410.1996.tb01296.x.
10
[Can thrombocyte crossmatching improve the efficiency of platelet transfusion?].血小板交叉配型能否提高血小板输注效率?
Beitr Infusionsther. 1990;26:160-2.

引用本文的文献

1
[Conventional vs pathogen-inactivated platelet concentrates for the treatment of perioperative coagulopathy. A prospective cohort study].[传统血小板浓缩物与病原体灭活血小板浓缩物治疗围手术期凝血病的前瞻性队列研究]
Chirurg. 2011 Apr;82(4):348-58. doi: 10.1007/s00104-010-2023-2.

本文引用的文献

1
The quantitative relation between platelet count and hemorrhage in patients with acute leukemia.急性白血病患者血小板计数与出血之间的定量关系。
N Engl J Med. 1962 May 3;266:905-9. doi: 10.1056/NEJM196205032661802.
2
Platelet transfusion therapy. One-hour posttransfusion increments are valuable in predicting the need for HLA-matched preparations.
JAMA. 1980 Feb 1;243(5):435-8. doi: 10.1001/jama.243.5.435.
3
Resonance-thrombography, theoretical and practical elements.
Biorheology. 1981;18(3-6):693-701. doi: 10.3233/bir-1981-183-631.
4
Which are the parameters to be controlled in platelet concentrates in order that they may be offered to the medical profession as a standardized product with specific properties?
Vox Sang. 1981 Feb;40(2):115-26.
5
Haemolytic transfusion reaction due to ABO incompatible plasma in a platelet concentrate.
Scand J Haematol. 1982 Mar;28(3):193-6. doi: 10.1111/j.1600-0609.1982.tb00514.x.
6
Transfusion problems associated with transplantation.与移植相关的输血问题。
Semin Hematol. 1981 Apr;18(2):163-76.
7
Controversies in platelet transfusion therapy.血小板输注治疗中的争议
Annu Rev Med. 1980;31:509-40. doi: 10.1146/annurev.me.31.020180.002453.
8
Granulocyte transfusions: current status.粒细胞输注:现状
Blood. 1980 Jan;55(1):2-8.
9
Donor transaminase and recipient hepatitis. Impact on blood transfusion services.供体转氨酶与受者肝炎。对输血服务的影响。
JAMA. 1981 Aug 7;246(6):630-4.
10
Buffy coat or platelet-rich plasma? Comparison of two platelet-processing techniques.
Vox Sang. 1984;47(2):108-13. doi: 10.1111/j.1423-0410.1984.tb01571.x.